NextCure Inc Annual Shareholders Meeting Transcript
Good morning and welcome to the 2026 Annual Meeting of the Stockholders of NextCure, Inc., being held virtually. I am David Kabakoff, Chair of the Board of Directors of NextCure. There are four items of business on todayâs agenda. First, the election of two Class I Directors. Second, the ratification of the appointment of Ernst & Young LLP as the companyâs independent registered public accounting firm for fiscal-year 2026.
Third, the approval on an advisory basis of the compensation paid by the company to its named executive officers. And fourth, the approval of an amendment and restatement of our 2019 Omnibus Incentive Plan. I will act as Chair of the meeting.
If any stockholder would like to comment on any of the proposals, please submit your comment using the Ask a Question feature on the website, and we will read comments at the indicated time. In addition, after the business portion of the meeting, we will answer stockholder questions. We will do our best to address as many as possible. However, comments or
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
